[Featured Stock] Kwang Dong Pharmaceutical Hits Upper Limit on 'Presbyopia Treatment FDA Approval'
Kwang Dong Pharmaceutical's share price has been rising for two consecutive days on news that a treatment for which it holds exclusive distribution rights in Korea has received approval from the U.S. Food and Drug Administration (FDA).
![[Featured Stock] Kwang Dong Pharmaceutical Hits Upper Limit on 'Presbyopia Treatment FDA Approval'](http://www.asiae.co.kr/news/img_view.htm?img=2025122209283864753_1766363319.jpg)
As of 9:10 a.m. on the 20th, Kwang Dong Pharmaceutical was trading at 10,400 won, up 30.00% (2,400 won) from the previous trading day.
The previous day as well, Kwang Dong Pharmaceutical surged 29.87% from the previous session to close at the upper price limit of 8,000 won.
Earlier, Kwang Dong Pharmaceutical announced that Uvegi, a presbyopia treatment for which it holds exclusive distribution rights in Korea, had received FDA approval.
Hot Picks Today
!["Big Gains for Holders... Up 566% and Still More to Go" Target Price Raised, But Here’s Why Caution Remains [Weekend Money]](https://cwcontent.asiae.co.kr/asiaresize/93/2025090513580721483_1757048288.jpg)
"Big Gains for Holders... Up 566% and Still More to Go" Target Price Raised, But Here’s Why Caution Remains [Weekend Money]
- "Data Centers Ignite ESS Order Rally Expectations for This Company [Weekend Money]"
- "Achieving 1 Billion Won Through Stocks" Office Worker Remains Optimistic Despite Mandatory Paid Leave and Halved Salary
- US Crackdown on Undocumented Immigrants Leads to Loss of 670,000 Jobs
- "Best Homeroom Teacher"... Hong Kong Education Sector in Shock Over Spread of "Princess Carry" Photos
Uvegi is a new drug developed by global biotech company Tenpoint Therapeutics, and in January 2024 Kwang Dong Pharmaceutical signed an exclusive license agreement with Hong Kong pharmaceutical company Zaoker, which holds the rights for the Asian region to this drug.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
